Sign in to view content

Characteristics and the Need for Supplementation Following 0.19mg Fluocinolone Acetonide (FAc) in Diabetic Macular Edema (DME) Patients

Victor Hugo Gonzalez, MD

Video
Published 2021

Related

Five-Year Outcomes After Initial Aflibercept, Bevacizumab, or Ranibizumab Treatment for Diabetic Macular Edema (Protocol T)
Dante Joseph Pieramici, MD
Annual Meeting Talks
2020
ASRS Updates in the Management of Diabetic Retinopathy DME and PDR in the Middle East and Africa
Sunir J. Garg, MD, FACS, FASRS
Webinars and Journal Clubs
2023
Anti-VEGF treatment switch in DME and nAMD: a comparison of aflibercept versus ranibizumab after a single-dose switch
Estephania Feria, MD
On Demand Cases, Courses, and Papers
2019

Category: Diabetic Retinopathy

See more